Login to Your Account



Pharma: Other News To Note


Friday, February 1, 2013
• Pfizer Inc., of New York, said the District Court of Delaware ruled that its patent covering a method for using sirolimus, the active ingredient in Rapamune, for the inhibition of organ transplant rejection is valid and infringed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription